Abe Bassan is a Principal at Samsara BioCapital, where he focuses on launching and supporting innovative therapeutics companies. Abe previously served as Director of program biology at Revolution Medicines, where he co-led the company’s mTORC1 cancer program. Prior to that, he was Associate Director of program development at bluebird bio, where he was the project manager for several of the company’s gene therapy programs. Earlier in his career, Abe was an associate at Third Rock Ventures, where he played a leading role in the firm’s investment in bluebird bio, as well as the ideation of Blueprint Medicines, a precision medicine oncology company. In addition to Septerna, he currently serves on the boards of Graphite Bio, Vedere Bio, and Syncopation Life Sciences.
Abe received an A.B. in Molecular Biology from Princeton University, and an M.S. in Developmental Biology from Stanford University.